Keep Current with the Latest in Cell Biology Research
A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer
[A2 Biotherapeutics, Inc.] A2 Biotherapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation to A2B530 for the treatment of germline heterozygous patients with colorectal cancer that expresses carcinoembryonic antigen and has lost HLA-A*02 expression.
Intestinal Epithelial Krüppel-Like Factor 4 Alleviates Endotoxemia and Atherosclerosis through Improving NF-κB/miR-34a-Mediated Intestinal Permeability
[Acta Pharmacologica Sinica] The authors investigated the role of krüppel-like factor 4 in regulating intestinal inflammation and permeability during the atherosclerotic process.
Cancer Associated Fibroblasts-Derived SULF1 Promotes Gastric Cancer Metastasis and CDDP Resistance through the TGFBR3-Mediated TGF-β Signaling Pathway
[Cell Death Discovery] Scientists examined the role and underlying molecular mechanisms of human sulfatase 1 (SULF1) in the context of gastric cancer.
KCTD15 Acts as an Anti-tumor Factor in Colorectal Cancer Cells Downstream of the Demethylase FTO and the m6A Reader YTHDF2
[Communications Biology] Tetracycline induced overexpression and knockdown of potassium channel tetramerization domain containing 15 (KCTD15) confirms KCTD15 as an anti-proliferative and pro-apoptotic factor in colorectal cancer both in vitro and in xenografted tumors.
[Mercer University] The National Cancer Institute awarded a $143,000 grant to Dr. Mahavir Bhupal Chougule, associate professor of pharmaceutical sciences, to develop first-in-class medicines that will block the function of human epidermal growth factor receptor 2 in this form of breast cancer.
Everolimus Decreases [U-13C]glucose Utilization by Pyruvate Carboxylase in Breast Cancer Cells In Vitro and In Vivo
[Biomedicine & Pharmacotherapy] Researchers investigated whether the effects of a drug combination on tumor size is reflected in changes in tumor metabolism using [U-13C]glucose labeling in a triple negative breast cancer xenograft model.
[UCLA Samueli School of Engineering] The Chan Zuckerberg Initiative today announced a $4 million grant to support research led by the UCLA Samueli School of Engineering that will examine cellular behaviors, many of which play a key role in developing immunity to pathogens and disease.
Lipid Nanoparticles and siRNA Targeting Plasminogen Provide Lasting Inhibition of Fibrinolysis in Mouse and Dog Models of Hemophilia A
[Science Translational Medicine] The authors developed a long-lasting antifibrinolytic using small interfering RNA targeting plasminogen packaged in clinically used lipid nanoparticles and tested it to determine whether reducing plasmin activity in animal models of hemophilia A could decrease bleeding frequency and severity.
An Engineered Baculoviral Protein and DNA Co-Delivery System for CRISPR-Based Mammalian Genome Editing
[Nucleic Acids Research] Using protein-loaded baculovirus, the authors demonstrated delivery of Cas9 or base editors proteins, leading to efficient genome and base editing in human cells.
Ex Vivo Expansion of Hematopoietic Stem Cells in Two/ Three-Dimensional Co-Cultures with Various Source of Stromal Cells
[Tissue And Cell] The capacity of mesenchymal stem cells derived from different sources to support the expansion and maintenance of HSPC was compared with each other.
Integrative Single-Cell Expression and Functional Studies Unravels a Sensitization to Cytarabine-Based Chemotherapy Through HIF Pathway Inhibition in AML Leukemia Stem Cells
[Hemasphere] Scientists identified HIFhigh and HIFlow specific AML subgroups and provided a comprehensive single-cell expression atlas of 119,000 AML cells and AML-leukemia stem cells in paired diagnostic-relapse samples from these molecular subgroups.
Improving Hematopoietic Differentiation from Human Induced Pluripotent Stem Cells by the Modulation of Hippo Signaling with a Diarylheptanoid Derivative
[Stem Cell Research & Therapy] Researchers utilized a defined cocktail of cytokines without serum or feeder followed by the supplementation of ASPP 049 to produce hematopoietic stem/progenitor cells.